PIRAMAL PHARMA share price has zoomed 6% and is presently trading at Rs 177.1.
Meanwhile, the BSE HEALTHCARE index is at 40,750.0 (up 1.8%).
Among the top gainers in the BSE HEALTHCARE index today are AJANTA PHARMA (up 5.6%) and ASTER DM HEALTHCARE (up 4.4%).
GLAND PHARMA (down 4.1%) and FORTIS HEALTHCARE (down 2.5%) are among the top losers today.
Over the last one year, PIRAMAL PHARMA has moved up from Rs 101.7 to Rs 177.1, registering a gain of Rs 75.5 (up 74.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 40,750.0, registering a gain of 44.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 114.5%), SUVEN PHARMACEUTICALS (up 104.6%) and GRANULES INDIA (up 104.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,346.8 (up 1.0%).
The top gainers among the BSE Sensex today are MUNDRA PORT & SEZ (up 3.1%) and Power Grid Corp. (up 3.0%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 24,273.4 (up 1.2%). ONGC and Coal India are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 79,346.8, registering a gain of 13,393.3 points (up 20.3%).
PIRAMAL PHARMA net profit grew 1.7% YoY to Rs -1,110 million for the quarter ended June 2024, compared to a loss of Rs 1,130 million a year ago. Net sales rose 11.6% to Rs 19,511 million during the period as against Rs 17,489 million in April-June 2023.
For the year ended March 2024, PIRAMAL PHARMA reported 109.6% increase in net profit to Rs 178 million compared to net loss of Rs 1,865 million during FY23. Revenue of the company grew 15.4% to Rs 81,712 million during FY24.
The current Price to earnings ratio of PIRAMAL PHARMA, based on rolling 12 month earnings, stands at -590.9.
Equitymaster requests your view! Post a comment on "PIRAMAL PHARMA Gains 6%; BSE HEALTHCARE Index Up 1.8%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!